Your SlideShare is downloading. ×
0
MeTA Process and Progress in Jordan
MeTA Process and Progress in Jordan
MeTA Process and Progress in Jordan
MeTA Process and Progress in Jordan
MeTA Process and Progress in Jordan
MeTA Process and Progress in Jordan
MeTA Process and Progress in Jordan
MeTA Process and Progress in Jordan
MeTA Process and Progress in Jordan
MeTA Process and Progress in Jordan
MeTA Process and Progress in Jordan
MeTA Process and Progress in Jordan
MeTA Process and Progress in Jordan
MeTA Process and Progress in Jordan
MeTA Process and Progress in Jordan
MeTA Process and Progress in Jordan
MeTA Process and Progress in Jordan
MeTA Process and Progress in Jordan
MeTA Process and Progress in Jordan
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

MeTA Process and Progress in Jordan

1,259

Published on

A presentation describing how the Medicines Transparency Alliance is set up in Jordan and the work it proposes to do, by Dr Rania Bader, made at the launch of MeTA Jordan in May 2009.

A presentation describing how the Medicines Transparency Alliance is set up in Jordan and the work it proposes to do, by Dr Rania Bader, made at the launch of MeTA Jordan in May 2009.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1,259
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
11
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide
  • Title of presentation 10/06/09 MeTA
  • Transcript

    • 1. Rania Bader MeTA Consultant MeTA Process and Progress in Jordan MeTA 10/06/09
    • 2. Jordan’s Fact Sheet <ul><li>Population: 5.8 million </li></ul><ul><li>Health expenditure: 10.4 % of GDP </li></ul><ul><li>(30% of this spent on medicines) </li></ul><ul><li>Total Medicine Expenditure $ 338 Million </li></ul><ul><li>Public Medicine Expenditure $ 112.6 Million </li></ul><ul><li>25% Medicine expenditure (public sector) </li></ul><ul><li>75 % Medicine expenditure (private sector) </li></ul><ul><li>Local medicines manufacturers: 16 </li></ul><ul><li>Medicines expenditure growth 17% per </li></ul><ul><li>annum compared to GDP growth of 3.3% </li></ul>10/06/09 MeTA
    • 3. What is MeTA? <ul><li>MeTA brings together at the international and national levels, a diverse group of people working in the pharmaceutical sector through a ( multi-stakeholders approach ) to find ways to improve/increase transparency and accountability in selection, regulation, procurement, distribution and use of medicines in countries </li></ul><ul><li>MeTA partners are the UK Department for International Development ( DFID ) , the WHO and the World Bank (WB) </li></ul>10/06/09 MeTA
    • 4. Agenda <ul><li>A. MeTA Process in Jordan </li></ul><ul><li>B. MeTA Progress in Jordan ( achievements so far) </li></ul><ul><li>C. Monitoring and Evaluation </li></ul><ul><li>D. Challenges </li></ul><ul><li>E. Key Successes </li></ul><ul><li>F. Getting more information </li></ul>10/06/09 MeTA
    • 5. MeTA Process in Jordan: <ul><li>It started with scoping visits </li></ul><ul><li>Looked into reasons for Jordan to be one of the MeTA pilot Countries </li></ul><ul><li>Proposal was sent to the Government </li></ul><ul><li>The Government approved </li></ul><ul><li>Formed the MeTA Council / stakeholder </li></ul><ul><li>Drafting Jordan’s Workplan </li></ul><ul><li>MOU signed </li></ul>10/06/09 MeTA
    • 6. <ul><li>MeTA in Jordan </li></ul>10/06/09 MeTA
    • 7. MeTA Process in Jordan: <ul><li>The Minister of Health sent an official letter to MOPIC approving on having the High Health Council (HHC) hosting the MeTA Secretariat </li></ul>10/06/09 MeTA
    • 8. MeTA Process in Jordan: <ul><li>Jordan’s MeTA Council held its first meeting at the HHC in August 2008 after the MeTA council was formed and endorsed by the MOH, the council representation is from the Government, private sector, civil society organizations, professional organizations, and the academia. In addition non- voting representatives from the World Bank (WB), the World Health Organization (WHO) and Health Action international (HAI), with the presence of the MeTA national consultant in Jordan </li></ul>10/06/09 MeTA
    • 9. MeTA Process in Jordan: <ul><li>T he Council serves as the highest policy making and consultative body </li></ul><ul><li>The council elected his chairperson Dr Taher AbuElSamen and also nominated him to participate as Jordan’s representative on the MeTA International Advisory Group (MIAG) in London every year </li></ul>10/06/09 MeTA
    • 10. MeTA Process in Jordan: <ul><li>The MeTA Council drafted the internal rules and formed Three Committees then developed activities for the areas of work that they chose and included them in the Jordan MeTA workplan </li></ul><ul><li>Jordan MeTA workplan has been sent officially to the MMB on the 9 th of February 2009 for approval, and it was approved after 7 working days, MOU was signed accordingly </li></ul>10/06/09 MeTA
    • 11. MeTA Process in Jordan: <ul><li>The three committees that have been formed out of the MeTA Council are: </li></ul><ul><li>1- Evidence Based Decision Making for the RDL Committee </li></ul><ul><li>2- Encouraging Best Practice and Promote Rational Drug Use Committee </li></ul><ul><li>3- Civil Society organizations Building Capacity Committee </li></ul>10/06/09 MeTA
    • 12. MeTA Progress in Jordan <ul><li>Supply Chain Mapping </li></ul><ul><li>Private Sector Mapping </li></ul><ul><li>CSO Mapping </li></ul><ul><li>NICE Training on Using Health Technology Assessment to inform decision-making in healthcare </li></ul><ul><li>MeTA Chair has Participated in the MIAG meeting </li></ul><ul><li>Held an important session on medicines and transparency at the WHA </li></ul>10/06/09 MeTA
    • 13. WHA 62 Geneva 2009 <ul><li>MeTA Jordan held an important session on medicines and transparency and Good Governance at the WHA, Geneva, on19th May. Over 80 participants from the WHA attended with representatives from over 20 different countries including Iraq, Libia,Ghana, Cameroon, Peru, Argentina, India, and Bangladesh </li></ul><ul><li>Members of the MeTA Jordan Council presented the work they have done so far in setting up a multi-stakeholder group comprising representatives from Government, the pharmaceutical industry, and civil society organizations </li></ul>10/06/09 MeTA
    • 14. Monitoring and Evaluation <ul><ul><ul><li>Monthly progress reports of three working committees and MeTA Jordan Secretariat </li></ul></ul></ul><ul><ul><ul><li>Quarterly reports by MeTA Council to International MeTA Secretariat Reports will be published on national & international MeTA websites </li></ul></ul></ul><ul><ul><ul><li>Financial reporting by national MeTA Secretariat </li></ul></ul></ul><ul><ul><ul><li>External monitor from another MeTA pilot country on annual and also the CSO Alliance could be involved in the monitoring and evaluation process </li></ul></ul></ul>10/06/09 MeTA
    • 15. Challenges <ul><li>Assuring commitment & engagement of ALL stakeholders </li></ul><ul><li>Clarity and understanding of MeTA’s objectives to Jordan’s MeTA Council stakeholders at ALL levels of their organisations </li></ul><ul><li>Lack of good quality information and data </li></ul><ul><li>Civil Society are in early stages of development </li></ul><ul><li>How to make the MeTA approach SUSTAINABLE </li></ul><ul><li>The concept behind MeTA processes to be country-led, that in a way caused the process in Jordan to be slower </li></ul>10/06/09 MeTA
    • 16. Key Successes <ul><li>The full support from the Jordanian government, MOH and MOPIC </li></ul><ul><li>The full support from the international MeTA Secretariat </li></ul><ul><li>WHO Jordan Country Representative was very supportive </li></ul>10/06/09 MeTA
    • 17. Key Successes <ul><li>DFID, WHO/HQ, WB and WHO/EMRO regional office were very supportive </li></ul><ul><li>Cooperation between all stakeholders including the private sector and the Council members from all sectors were highly committed to moving the MeTA process forward </li></ul>10/06/09 MeTA
    • 18. References for getting more Information: <ul><li>http://www.medicinestransparency.org/meta-countries/jordan/ </li></ul><ul><li>http://www.haiweb.org/medicineprices/surveys/200405JO/survey_report.pdf </li></ul><ul><li>http://www.medicinestransparency.org/fileadmin/uploads/Documents/WHA-Briefing-note.pdf </li></ul><ul><li>http://www.medicinestransparency.org/fileadmin/uploads/Documents/WHA-MeTA-Country-Jordan.pdf </li></ul><ul><li>http://www.medicinestransparency.org/fileadmin/uploads/Documents/WHO-HAI-summary-report.pdf </li></ul><ul><li>http://www.medicinestransparency.org/news-events/article/view/information-about-medicines-where-to-start/80/ </li></ul>10/06/09 MeTA
    • 19. Thank you! <ul><li>Rania Bader </li></ul><ul><li>Email: raniasb2002@yahoo.com </li></ul><ul><li>Mobile number +962 79 5691921 </li></ul><ul><li>MeTA: www.MedicinesTransparency.org </li></ul>10/06/09 MeTA

    ×